Mydane

Lidocaine Hydrochloride, Phenylephrine Hydrochloride and Tropicamide, the active ingredients in Mydane, are a combination ophthalmic preparation presented as a solution for injection for intracameral use. It provides local anesthesia and pupil dilation during ophthalmic surgery in adult patients.

GNH USA supplies Mydane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Mydane, a combination ophthalmic preparation, is employed to achieve intra‑operative mydriasis and local anesthesia in anterior segment eye procedures.

Intra‑operative mydriasis: sustains pupil dilation throughout ophthalmic surgery. Local anesthesia of the anterior chamber: numbs the anterior segment to facilitate procedures. Pain reduction during surgery: minimizes patient discomfort during cataract or glaucoma operations.

Mydane may cause transient ocular reactions and systemic effects following intracameral administration.

Common Side Effects: - Burning or stinging sensation in the eye. - Temporary blurred vision. - Mild conjunctival redness. - Transient increase in intra‑ocular pressure. - Mild headache. - Nausea.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) with swelling, rash, or difficulty breathing. - Persistent high intra‑ocular pressure. - Corneal edema or ulceration. - Endophthalmitis (intra‑ocular infection). - Cardiac arrhythmias due to systemic absorption of phenylephrine. - Vision loss.

Prior to using Mydane, clinicians should assess patient history and ocular condition.

Allergy assessment: confirm no known hypersensitivity to lidocaine, phenylephrine, or tropicamide. Cardiovascular status: avoid in patients with uncontrolled hypertension or arrhythmias. Pregnancy and lactation: use only if benefit outweighs potential risk. Intra‑ocular infection: defer use in active ocular infections. Monitoring: observe intra‑ocular pressure and pupil size after administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mydane may interact with systemic medications that affect cardiovascular or ocular physiology.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis with phenylephrine. - Beta‑blockers: may blunt phenylephrine‑induced pupil dilation. - Other local anesthetics: additive toxicity risk.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may enhance cycloplegic effect of tropicamide. - Systemic sympathomimetics: may increase cardiovascular effects. - CYP450 substrates: phenylephrine metabolism may be altered by enzyme inhibitors.